vs

Side-by-side financial comparison of Lineage Cell Therapeutics, Inc. (LCTX) and PURE CYCLE CORP (PCYO). Click either name above to swap in a different company.

PURE CYCLE CORP is the larger business by last-quarter revenue ($9.1M vs $6.6M, roughly 1.4× Lineage Cell Therapeutics, Inc.). PURE CYCLE CORP runs the higher net margin — 50.0% vs 12.9%, a 37.1% gap on every dollar of revenue. On growth, Lineage Cell Therapeutics, Inc. posted the faster year-over-year revenue change (130.4% vs 58.8%). Over the past eight quarters, Lineage Cell Therapeutics, Inc.'s revenue compounded faster (113.9% CAGR vs 69.0%).

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...

Pure Cycles, is a bicycle company based in Los Angeles, California that was founded by Michael Fishman, Jordan Schau, Zachary Schau and Austin Stoffers in 2010, as Pure Fix Cycles.

LCTX vs PCYO — Head-to-Head

Bigger by revenue
PCYO
PCYO
1.4× larger
PCYO
$9.1M
$6.6M
LCTX
Growing faster (revenue YoY)
LCTX
LCTX
+71.6% gap
LCTX
130.4%
58.8%
PCYO
Higher net margin
PCYO
PCYO
37.1% more per $
PCYO
50.0%
12.9%
LCTX
Faster 2-yr revenue CAGR
LCTX
LCTX
Annualised
LCTX
113.9%
69.0%
PCYO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
LCTX
LCTX
PCYO
PCYO
Revenue
$6.6M
$9.1M
Net Profit
$851.0K
$4.6M
Gross Margin
68.4%
Operating Margin
-99.1%
48.0%
Net Margin
12.9%
50.0%
Revenue YoY
130.4%
58.8%
Net Profit YoY
126.0%
16.0%
EPS (diluted)
$0.00
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LCTX
LCTX
PCYO
PCYO
Q4 25
$6.6M
$9.1M
Q3 25
$3.7M
$11.2M
Q2 25
$2.8M
$5.1M
Q1 25
$1.5M
$4.0M
Q4 24
$2.9M
$5.8M
Q3 24
$3.8M
$12.6M
Q2 24
$1.4M
$7.6M
Q1 24
$1.4M
$3.2M
Net Profit
LCTX
LCTX
PCYO
PCYO
Q4 25
$851.0K
$4.6M
Q3 25
$-29.8M
$6.1M
Q2 25
$-30.5M
$2.3M
Q1 25
$-4.1M
$809.0K
Q4 24
$-3.3M
$3.9M
Q3 24
$-3.0M
$6.6M
Q2 24
$-5.8M
$2.8M
Q1 24
$-6.5M
$118.0K
Gross Margin
LCTX
LCTX
PCYO
PCYO
Q4 25
68.4%
Q3 25
67.7%
Q2 25
63.4%
Q1 25
97.6%
38.2%
Q4 24
94.6%
63.8%
Q3 24
99.0%
77.8%
Q2 24
96.9%
64.0%
Q1 24
93.2%
55.6%
Operating Margin
LCTX
LCTX
PCYO
PCYO
Q4 25
-99.1%
48.0%
Q3 25
-102.9%
53.1%
Q2 25
-715.4%
26.0%
Q1 25
-433.1%
-33.2%
Q4 24
-178.2%
29.9%
Q3 24
-101.6%
62.0%
Q2 24
-416.7%
40.3%
Q1 24
-461.3%
-11.5%
Net Margin
LCTX
LCTX
PCYO
PCYO
Q4 25
12.9%
50.0%
Q3 25
-809.0%
54.5%
Q2 25
-1101.8%
43.9%
Q1 25
-275.6%
20.3%
Q4 24
-114.1%
68.4%
Q3 24
-80.3%
52.6%
Q2 24
-409.1%
37.2%
Q1 24
-453.0%
3.7%
EPS (diluted)
LCTX
LCTX
PCYO
PCYO
Q4 25
$0.00
$0.19
Q3 25
$-0.13
$0.26
Q2 25
$-0.13
$0.09
Q1 25
$-0.02
$0.03
Q4 24
$0.00
$0.16
Q3 24
$-0.02
$0.27
Q2 24
$-0.03
$0.12
Q1 24
$-0.04
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LCTX
LCTX
PCYO
PCYO
Cash + ST InvestmentsLiquidity on hand
$55.8M
$17.1M
Total DebtLower is stronger
$8.0M
Stockholders' EquityBook value
$44.5M
$147.5M
Total Assets
$112.6M
$168.1M
Debt / EquityLower = less leverage
0.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LCTX
LCTX
PCYO
PCYO
Q4 25
$55.8M
$17.1M
Q3 25
$40.5M
$21.9M
Q2 25
$42.3M
$14.4M
Q1 25
$47.9M
$16.5M
Q4 24
$47.8M
$19.0M
Q3 24
$32.7M
$22.1M
Q2 24
$38.5M
$20.5M
Q1 24
$43.6M
$20.6M
Total Debt
LCTX
LCTX
PCYO
PCYO
Q4 25
$8.0M
Q3 25
$6.8M
Q2 25
$6.9M
Q1 25
$6.9M
Q4 24
$6.9M
Q3 24
$6.9M
Q2 24
Q1 24
Stockholders' Equity
LCTX
LCTX
PCYO
PCYO
Q4 25
$44.5M
$147.5M
Q3 25
$22.0M
$142.7M
Q2 25
$48.4M
$136.7M
Q1 25
$79.0M
$134.4M
Q4 24
$78.4M
$133.6M
Q3 24
$66.2M
$129.7M
Q2 24
$68.3M
$123.2M
Q1 24
$72.4M
$120.4M
Total Assets
LCTX
LCTX
PCYO
PCYO
Q4 25
$112.6M
$168.1M
Q3 25
$89.6M
$162.3M
Q2 25
$90.8M
$151.7M
Q1 25
$111.8M
$149.7M
Q4 24
$113.2M
$149.7M
Q3 24
$96.6M
$147.4M
Q2 24
$102.8M
$140.4M
Q1 24
$108.5M
$135.2M
Debt / Equity
LCTX
LCTX
PCYO
PCYO
Q4 25
0.05×
Q3 25
0.05×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.05×
Q3 24
0.05×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LCTX
LCTX
PCYO
PCYO
Operating Cash FlowLast quarter
$-4.9M
$-979.0K
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-79.9%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
-5.73×
-0.21×
TTM Free Cash FlowTrailing 4 quarters
$-19.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LCTX
LCTX
PCYO
PCYO
Q4 25
$-4.9M
$-979.0K
Q3 25
$-3.6M
$9.4M
Q2 25
$-5.5M
$-503.0K
Q1 25
$-4.9M
$-1.4M
Q4 24
$-6.3M
$5.7M
Q3 24
$-5.8M
$3.1M
Q2 24
$-5.2M
$892.0K
Q1 24
$-5.8M
$-457.0K
Free Cash Flow
LCTX
LCTX
PCYO
PCYO
Q4 25
$-5.3M
Q3 25
$-3.6M
Q2 25
$-5.6M
Q1 25
$-5.0M
Q4 24
$-6.7M
Q3 24
$-5.9M
Q2 24
$-5.2M
Q1 24
$-5.8M
FCF Margin
LCTX
LCTX
PCYO
PCYO
Q4 25
-79.9%
Q3 25
-98.6%
Q2 25
-200.8%
Q1 25
-331.8%
Q4 24
-234.0%
Q3 24
-156.1%
Q2 24
-371.2%
Q1 24
-403.1%
Capex Intensity
LCTX
LCTX
PCYO
PCYO
Q4 25
6.0%
Q3 25
0.3%
Q2 25
0.5%
Q1 25
6.5%
Q4 24
12.7%
Q3 24
3.0%
Q2 24
3.6%
Q1 24
2.6%
Cash Conversion
LCTX
LCTX
PCYO
PCYO
Q4 25
-5.73×
-0.21×
Q3 25
1.53×
Q2 25
-0.22×
Q1 25
-1.70×
Q4 24
1.44×
Q3 24
0.47×
Q2 24
0.32×
Q1 24
-3.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LCTX
LCTX

Collaboration Revenues$6.3M95%
Other$345.0K5%

PCYO
PCYO

Construction$6.5M71%
Water And Wastewater Resource Development Segment$2.5M27%

Related Comparisons